The ALS market was worth $148m in 2006 across the seven major markets. With the only approved treatment for ALS, Sanofi-Aventis's Rilutek (riluzole), facing generic incursion in 201213, future growth in this market is dependent on the success of pipeline drugs.

Scope

Scenario based analysis and forecasts of the commercial potential of the ALS market to 2016. Analysis of patient potential, marketing factors, commercial attractiveness and clinical attractiveness of key late-stage pipeline drugs. Strategic recommendations for maximizing the potential of drugs in this niche orphan disease market. Indication-specific sales forecasts of marketed and key pipeline drugs to 2016.

Highlights

A lack of new entrants, and the possibility of polytherapy, results in Sanofi-Aventis's Rilutek (riluzole) dominating the market until patent expiry in 2012-13 in Datamonitor's base scenario. Orphan drug status, rapid uptake following launch, limited risk to the company's share price if drugs fail, and possible indication expansions make long-term investment in ALS a commercially viable option. A scenario forecast based on the clinical success of rhIGF-1 (recombinant human insulin-like growth factor I) related therapies reveals a potentially lucrative market. However, with a high attrition rate of ALS Phase III clinical trials, and mixed efficacy data in Phase II, the results of currently underway studies will be pivotal.

Reasons to Purchase

Access the lucrative potential of this underdeveloped neurodegenerative disease therapeutic market. Benchmark key late-stage compounds against the current leading therapy Sanofi-Aventis's Rilutek (riluzole). Understand the opportunities in this market based on the comments of interviewed key opinion leaders.